1. Evaluation of a FLT3 Bite® for Acute Myeloid Leukemia
- Author
-
Goldstein, Rebecca, Henn, Anja, Koppikar, Priya, Archibeque, Ivonne, Frank, Brendon, Balazs, Mercedesz, Dahlhoff, Christoph, Raum, Tobias, Li, Chi-Ming, Wahl, Joachim, Rock, Dan, Thomas, Oliver, Karbowski, Christine, Krupka, Christina, Subklewe, Marion, Coxon, Angela, and Chapman-Arvedson, Tara
- Abstract
Acute myeloid leukemia (AML) is a disease with high unmet medical need. Standard induction chemotherapy can lead to complete remission in patients with a favorable genetic risk profile; however, about half of patients are ineligible for this intensive regimen. In those patients with a non-favorable genetic risk profile, the preferred treatment strategy is allogeneic stem cell transfer, but the majority of patients are ineligible due to age and other comorbidities.
- Published
- 2017
- Full Text
- View/download PDF